Date: 2015-03-15
Type of information: Development agreement
Compound:
Company: Evotec (Germany) Second Genome (USA - CA)
Therapeutic area:
Type agreement: development
Action mechanism:
Disease: microbiome-mediated diseases
Details: * On March 13, 2015, Evotec and Second Genome announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec’s integrated drug discovery platform. As part of the collaboration, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec’s technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.
Financial terms: Further financial terms were not disclosed.
Latest news:
